Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03648398
Other study ID # APPARA2018/EDUMICILOR-VELTIN
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date January 29, 2021
Est. completion date April 1, 2023

Study information

Verified date March 2021
Source Central Hospital, Nancy, France
Contact Muriel Veltin
Phone 0033383154187
Email muriel.veltin@micilor.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

EDUMICILOR is a monocentric prospective pilot study for patients with inflammatory bowel disease (IBD). During the study, patients will participate in an online therapeutic education program. They will first have an appointment with a nurse to establish a personalized educational diagnosis. Then they will participate in the online therapeutic education program for about 6 months (depends on the educational needs, expectations and patient's availabilities). The main objective of this study is to assess the feasibility of an online therapeutic education program for IBD patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date April 1, 2023
Est. primary completion date April 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Male or female (age = 18 years old) - Patients with established Crohn's disease or ulcerative colitis diagnosis - Patients who own the equipment to participate in the online therapeutic education program (computer, webcam….) - French speaking patients - Patients who cannot attend regular therapeutic education sessions at the hospital - Patients able to understand the information provided to them and to give written informed consent for the study Exclusion Criteria: - Patient who has not given his/her consent to participate

Study Design


Intervention

Other:
EDUMICILOR
Patients will participate in the online therapeutic education program for about 6 months

Locations

Country Name City State
France CHRU Nancy Nancy

Sponsors (1)

Lead Sponsor Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of participation in the online therapeutic education program Patients must participate in at least 80% of therapeutic education program sessions and connect to at least one video or one serious game. 6 months
Secondary Score of the Crohn and Colitis Knowledge Score The Crohn and Colitis Knowledge Score will assess the impact of the online therapeutic education program on achieving educational objectives. 6 months
Secondary Score of the short Inflammatory Bowel Disease Questionnaire (short-IBDQ) The short-IBDQ will assess the quality of life before and after the online therapeutic education program. 6 months
Secondary Score of the Inflammatory Bowel Disease Disability Index (IBD Disability Index) The IBD Disability index will be used to assess disability before and after the online therapeutic education program. 6 months
Secondary Score of the Hospital Anxiety and Depression Scale The Hospital Anxiety and Depression scale will assess the anxiety and depression level before and after the online therapeutic education program. 6 months
Secondary Score of the Girerd Scale The Girerd Scale will be used to assess the level of adherence to prescribed drugs before and after the online therapeutic education program. 6 months
Secondary Score of a satisfaction survey on the online therapeutic education program This survey will identify the advantages and disadvantages of an online therapeutic education program. 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05702879 - Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
Not yet recruiting NCT05953402 - A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
Recruiting NCT05316584 - A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy N/A
Recruiting NCT03950232 - An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis Phase 3
Completed NCT03124121 - Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels Phase 4
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Withdrawn NCT04209556 - A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis Phase 2
Terminated NCT00061282 - Clotrimazole Enemas for Pouchitis in Children and Adults Phase 1/Phase 2
Recruiting NCT04398550 - SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis N/A
Recruiting NCT04314375 - Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis Phase 4
Active, not recruiting NCT04857112 - Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis Phase 2
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Active, not recruiting NCT04033445 - A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Active, not recruiting NCT06221995 - Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
Recruiting NCT04767984 - Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis Phase 2
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Recruiting NCT06071312 - FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach Phase 1/Phase 2
Completed NCT03760003 - Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis Phase 2
Not yet recruiting NCT05539625 - Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis Phase 2